



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

NACM-OPT

Cat. No.:	HY-111505
CAS No.:	2089293-61-6
Molecular Formula:	C ₂₃ H ₂₉ Cl ₂ N ₃ O
Molecular Weight:	434.4
Target:	NEDD8-activating Enzyme; E1/E2/E3 Enzyme
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (287.75 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.3020 mL	11.5101 mL	23.0203 mL
		5 mM		0.4604 mL	2.3020 mL	4.6041 mL
		10 mM		0.2302 mL	1.1510 mL	2.3020 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	NACM-OPT is an orally bioavailable cullin neddylation 1 (DCN1) inhibitor, which potently inhibits the DCN1-UBE2M interaction ^[1] .
IC ₅₀ & Target	DCN1 ^[1]
In Vitro	NACM-OPT (Compound 67) is orally bioavailable, well tolerated in mice, and currently used to study the effects of acute pharmacologic inhibition of the DCN1-UBE2M interaction on the NEDD8/CUL pathway ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hammill JT, et al. Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem. 2018 Apr 12;61(7):2694-2706.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA